Journal Mobile Options
Table of Contents
Vol. 17, No. 5, 2008
Issue release date: August 2008
Section title: Original Paper
Open Access Gateway
Med Princ Pract 2008;17:415–418
(DOI:10.1159/000141508)

Olanzapine in the Treatment of Behavioral Problems Associated with Autism: An Open-Label Trial in Kuwait

Fido A.a · Al-Saad S.b
aDepartment of Psychiatry, Faculty of Medicine, Health Sciences Centre, Kuwait University, and bKuwait Autism Center, Kuwait
email Corresponding Author

Dr. Abdullahi Fido, MD, MRCPsych

Department of Psychiatry, Faculty of Medicine, Health Sciences Centre

Kuwait University, PO Box 24923

Safat 13110 (Kuwait)

Tel. +965 533 0467, Fax +965 533 8904, E-Mail fido@hsc.edu.kw


References

  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2002.
  2. Frombonne E: Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003;33:365–382.
  3. The Annual Statistical Abstract. Kuwait Autism Society 2006;2:51–58.
  4. Bailey A, Lecouteur A, Gottesman J: Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25:63–77.
  5. Piven J, Palmer P, Jacobi D: The broader autism phenotype: evidence from a family study of multiple-incidence autism families. Am J Psychiatry 1997;154:185–190.
  6. Sykes NH, Lamb JS: Autism: the quest for the genes. Expert Rev Mol Med 2007;9:1–15.
  7. Whitely P: A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 1999;3:45–65.

    External Resources

  8. Murch S: Diet, immunity, and autistic spectrum disorders. J Pediatr 2005;146:582–584.
  9. Janusonis S: Statistical distribution of blood serotonin as a predictor of early autistic brain abnormalties. Theor Biol Med Model 2007;19:2–27.
  10. Fido A, Dashti H, Al-Saad S: Biological correlates of childhood autism: ‘trace elements’. Trace Elem Electrol 2002;19:1–4.
  11. Fido A, Al-Saad S: Toxic trace elements in the hair of children with autism. Autism 2005;9:290–298.
  12. Dosman CF, Brian JA, Drmic IE: Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007;36:152–158.
  13. Adams JB, Romdalvik J, Ramanujam VM: Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health 2007;70:1046–1051.

    External Resources

  14. Horner RH, Carr EG, Strain PS: Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002;32:423–446.
  15. Hagopian LP, Pruzek JL, Bowman LG: Assessment and treatment of problem behavior occasioned by interruption of free-operant behavior. J Appl Behav Anal 2007;40:89–103.
  16. Jerome J, Frantino E, Sturmey P: The effects of errorless learning and backward chaining on the acquisition of internet skills in adults with developmental disabilities. J Appl Behav Anal 2007;40:185–189.
  17. Posey DJ, McDougle CJ: The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000;8:45–63.
  18. Aman MG: Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol 2004;11:225–228.
  19. Malone R, Maislin G, Choudhury M: Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. Am Acad Child Adolesc Psychiatry 2002;41:140–147.
  20. McCracken J, Mcgough J, Shah B: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314–321.
  21. Padina GJ, Bossie CA, Yousef E: Risperidone improves symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Autism Dev Disord 2007;37:367–373.

    External Resources

  22. West L, Waldrop J: Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nursing 2006;32:550–555.
  23. Potenza MN, Holmes JP, Kanes SJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37–44.
  24. Malone R, Cater J, Sheikh R: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Child Adolesc 2001;40:887–894.
  25. Kemner C, Willemsen S, Sophie H: Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455–460.
  26. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–676.
  27. Aman MG, Singh NN, Stewart AW: The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485–491.
  28. Hollander E, Wasserman S, Swanson EN: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541–548.